Maxime Journiac : ANRS-ISVHLD Paris July 5 2006 1 Obstacles to Hep C TREATMENT: The patient’s point of view.

Slides:



Advertisements
Similar presentations
1 0N-SITE TREATMENT OF HEPATITIS C - A PILOT STUDY Shay Keating, MB, PhD Medical Officer.
Advertisements

Hepatocirrhosis Liver cirrhosis.
Hepatitis C Treatment in Corrections: New Medicine, New Challenges
African Americans and Hepatitis C
World Hepatitis Day July 28th
Wisconsin D.O.C. Approach to Hepatitis C Treatment Edward Wall Secretary Jim Greer Bureau Director Health Services Wisconsin Department of Corrections.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Tuberculosis (TB) Facts
Hep 202 Just when you thought you knew everything.
Hepatitis C Disease & Treatment.
Hepatitis C testing Research Center for Genetic Engineering and Biotechnology “Georgi D. Efremov”, MASA What is Hepatitis C? Hepatitis C is a contagious.
Vaccine Information Statement Hepatitis B (7/11/01) 42 U.S.C. § 300aa-26.
Hepatitis C.
TREATING CANCEROUS CELLS HIV/AIDS HEPATITIS C Frank Lake & Immanuel Park.
You and Your Liver Amy V. Kindrick, M.D., M.P.H..
Foundation for Faith Based Organizations
MDL UMC utrecht Health Strategy on HCV in The Netherlands van Hattum VHPB meeting May 2002.
How long is the duration of treatment for XDR-TB? At least 2 years (the same as MDR-TB). Doctors will monitor people with any form of confirmed drug resistant.
for pregnant women and new moms
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
By: Taylor Lawrence.  Cirrhosis is a late stage of scarring (fibrosis) of the liver caused by many forms of liver diseases and conditions. This occurs.
Hepatitis B and C: A silent but deadly epidemic Arun J Sanyal M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University Richmond, Virginia.
Tuberculosis (T.B.) Randy Kim.
Departmental Perspectives on Viral Hepatitis
STD Review.
HCV/HIV coinfected patients in National Hospital for Tropical Diseases, Vietnam: genotypes, clinical manifestations and initial results in treating of.
Greenview Hepatitis C Fund Deborah Green Home: Cell: /31/2008.
Module 3: HCV prevalence and course of HCV infection.
Hepatitis C Education & Awareness. Women In Government Women In Government Foundation, Inc. is a national, non-profit, non-partisan organization of women.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Treatment.
SANTANA P. ABRAVANEL L., AUBERT JP.PICARD H. GELLY J. FRARIER M. 1 PREVAC A An evaluation of preventive Hepatitis A vaccination in risk groups WONCA EUROPE.
Adult Viral Hepatitis Update Roxanne Ereth, MPH, BS Hepatitis C Program Manager Adult Viral Hepatitis Prevention Coordinator.
Violation of Rights of People Living with HIV/AIDS in Health Care Setting in Odessa, Ukraine Odessa, Ukraine August 2008 Kostiantyn Zverkov, Director of.
Hepatitis C- Global and National Perspective Dr Allister Grant Consultant Hepatologist University Hospitals Leicester NHS Trust.
Meeting the health needs of older drug users Dr Muriel Simmonte NHS Lothian Primary Care Facilitator Team/East Lothian Locality Drug Clinic.
Wyoming Department of Health Communicable Diseases
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
HEPATITIS C IMPLICATIONS FOR HIV CARE & PREVENTION October 8, 2009.
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
HIV/ AIDS.
What is hepatitis B? Hepatitis B is a virus that infects the liver.
Patient Information - Viral Hepatitis B (HBV)
STD Review. Chlamydia- most common bacterial STD Caused by bacteria 75% of females, 50% of males have no symptoms Transmitted through all types of sexual.
HEPATITIS MOBILE TEAM News Tools of screening viral hepatitis in real life: the french model of care André-Jean REMY (1,2), Hugues WENGER (1), Hakim BOUCKHIRA.
1 Care for Injection Drug Users (IDUs) with HIV HAIVN Havard Medical School AIDS Initiative in Vietnam.
All About Blood Borne Pathogens
+ By: Sydney Freedman. + General Background 1895: Germany, smallpox outbreak Led to Jaundice Liver doesn’t destroy blood cells properly 1942: United States,
Co-infections TB/HIV in prison Côte d’Ivoire Case study Doctor J-M MASUMBUKO ESTHER Coordinator in Côte d’ivoire 24 July th IAC,
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
Hepatitis C.
Hepatitis is an inflammation of the liver. The condition can be self- limiting or can progress to fibrosis (scarring), cirrhosis or liver cancer WHAT IS.
FDA Hepatitis C Hearing Oct 19, 2006 Jules Levin Executive Director/Founder, NATAP National AIDS Treatment Advocacy Project.
1 Adherence to ARV Therapy and Resistance HAIVN Havard Medical School AIDS Initiative in Vietnam.
Blood Borne Infections AIDS & HEPATITIS B Prevention for Healthcare Workers There is others out there!
Trends in Treatment of Recurrent Hepatitis C After Liver Transplantation Kate Forgan-Smith KA Stuart 1,4, C Tallis 1,4 GA Macdonald 1,3,4, J Fawcett 2,3.
Karyn Kaplan Thai AIDS Treatment Action Group (TTAG)
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
Hepatitis C Infection By: S/N Maryam Omar. Introduction  Thalassemia patient require life long blood transfusion to sustain their growth and development.
Virology – Antivirals 2 JU- 2 nd Year Medical Students By Dr Hamed AlZoubi – Microbiology and Immunology Department – Mutah University. MBBS (J.U.S.T)
Hepatitis C and Sexual & Reproductive Health Graham Mackintosh, Training & Capacity Officer Lesley Bon, Patient Involvement Officer.
Section 1: Introduction Dr Somen Banerjee, Director of Public Health London Borough Tower Hamlets.
on theme: «Botkin’s Disease»
Documenting barriers to access HCV care and treatment: a peer-led research João Santa Maria, Magda Ferreira, Renato Pinto, Joana Sanches, Álvaro Ávila,
Hepatitis C Screening Best Practices Jenitza Serrano-Feliciano M.D
Community Intervention Strategies
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
More Than Treatment.
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Just when you thought you knew everything.
Presentation transcript:

Maxime Journiac : ANRS-ISVHLD Paris July Obstacles to Hep C TREATMENT: The patient’s point of view

Maxime Journiac : ANRS-ISVHLD Paris July Background 30 to 35% of HIV French Positive patients are also co-infected with Hep C and/or Hep B/Delta which represent 35 to persons 30 to 35% of HIV French Positive patients are also co-infected with Hep C and/or Hep B/Delta which represent 35 to persons More than 40% of French co-infected patients seen in hospital are F3 or F4 and a growing number is developping a severe cirhosis and /or liver cancer More than 40% of French co-infected patients seen in hospital are F3 or F4 and a growing number is developping a severe cirhosis and /or liver cancer End Stage Liver Disease is the first cause of death amongst co-infected French patients End Stage Liver Disease is the first cause of death amongst co-infected French patients

Maxime Journiac : ANRS-ISVHLD Paris July Obstacles to a first treatment Obstacles to a first treatment Lack of Information about the treatment, the adverse events Lack of Information about the treatment, the adverse events Lack of testing Lack of testing Fear of liver biopsy Fear of liver biopsy Long delay to access a specialist Long delay to access a specialist Negative representation of Hep C treatment Negative representation of Hep C treatment Population with different priorities and special needs (Alcohol and dug users, Prisonners, Homeless People, Undocumented workers and Migrants) Population with different priorities and special needs (Alcohol and dug users, Prisonners, Homeless People, Undocumented workers and Migrants)

Maxime Journiac : ANRS-ISVHLD Paris July Obstacles to a 2nd or more treatment (1) Obstacles to a 2nd or more treatment (1) Difficult experience with the first treatment (fatigue, depression, irritability, lack of concentration, skin and mucosal problems, weight loss, sexual problems, blood and other abnormalities,…) Difficult experience with the first treatment (fatigue, depression, irritability, lack of concentration, skin and mucosal problems, weight loss, sexual problems, blood and other abnormalities,…) Unsufficient global care Unsufficient global care Poor tolerance to treatment (poor quality of life…) Poor tolerance to treatment (poor quality of life…) Poor adverse events management Poor adverse events management Psycho social difficulties (lack of governemental social programmes) Psycho social difficulties (lack of governemental social programmes)

Maxime Journiac : ANRS-ISVHLD Paris July Obstacles to a 2nd or more treatment (2) Obstacles to a 2nd or more treatment (2) All treatments include Peg IFN and Ribavirine which are particularly toxic to co-infected patients All treatments include Peg IFN and Ribavirine which are particularly toxic to co-infected patients Development of complications over time Development of complications over time In spite of viral clearance, cirrhosis may continue to develop In spite of viral clearance, cirrhosis may continue to develop Poor results at a high cost Poor results at a high cost

Maxime Journiac : ANRS-ISVHLD Paris July What we need Better Information Better Information Validated Non Invasive Tests Validated Non Invasive Tests Easy to use injecting devices Easy to use injecting devices Less toxic drugs (Ribavirine) Less toxic drugs (Ribavirine) Access to Epoetin and G-CSF to patients in need Access to Epoetin and G-CSF to patients in need All co-infected patients (>F2) should be seen by an infectiologist and an hepatologist All co-infected patients (>F2) should be seen by an infectiologist and an hepatologist A better global care including medical and psycho social care, support and management of adverse events A better global care including medical and psycho social care, support and management of adverse events Quicker referral to the transplantation lists Quicker referral to the transplantation lists

Maxime Journiac : ANRS-ISVHLD Paris July Conclusion (1) Conclusion (1) We need a real pluridisciplinary and global care We need a real pluridisciplinary and global care Doctors have to stop wondering if they use EPO and G-CSF and start finding the right doses for a better benefit/risk ratio for the patients Doctors have to stop wondering if they use EPO and G-CSF and start finding the right doses for a better benefit/risk ratio for the patients New Molecules and new strategies New Molecules and new strategies An anti Hep C vaccine An anti Hep C vaccine We have to come up with strategies of treatment for non responding patients We have to come up with strategies of treatment for non responding patients

Maxime Journiac : ANRS-ISVHLD Paris July Conclusion (2) Remember that you are not only treating a virus and an organ but a whole person with his/her own needs, priorities and specificities. Remember that you are not only treating a virus and an organ but a whole person with his/her own needs, priorities and specificities.

Maxime Journiac : ANRS-ISVHLD Paris July Aknowledgements I want to thank my colleagues from CHV, TRT-5, EATG and all the co-infected patients that I have met over the years who’ve help me gather all these informations I want to thank my colleagues from CHV, TRT-5, EATG and all the co-infected patients that I have met over the years who’ve help me gather all these informations I also want to thank all the dedicated ANRS infectiologists and hepatologists from the AC 24 (hepatitis group) and co-infection group who do their best to fight for a better care for us I also want to thank all the dedicated ANRS infectiologists and hepatologists from the AC 24 (hepatitis group) and co-infection group who do their best to fight for a better care for us Last but not least I want to thank my doctor (she knows who she is) Last but not least I want to thank my doctor (she knows who she is)